Roche Products Ltd is proud to fund grants that enhance patient care, offer meaningful support and aim to advance the NHS healthcare delivery. We are thrilled to announce the “Call for Grants in SMA Programme 2025”. This initiative aims to help address health inequalities and expand knowledge of SMA ultimately leading to improved outcomes for people living with SMA and help to strengthen the healthcare system.
Roche is inviting healthcare organisations, healthcare-related entities and patient organisations based in the UK to submit a grant application.
Roche deeply understands the vital role newborn screening plays within the SMA community. While this specific topic is not included in our grants programme, we remain committed to supporting impactful projects in this area through other dedicated initiatives.
Our prioritised themes in scope of the programme:
Addressing inequalities in access to healthcare
Reducing disparities in access to critical healthcare services for people living with SMA
Understanding the evolving needs of people living with SMA
Understanding the impact of the changing phenotype of people living with SMA including their changing needs in areas such as school support services, cognitive support, mental health etc.
SMA research and evidence generation
Generating robust evidence to enhance understanding of key areas including (but not limited to) cognition, respiratory function, bulbar function, fertility, among people living with SMA receiving disease-modifying treatments.
Care transition from paediatric to adult services and continuity of care
Understanding and addressing the transition from paediatric to adult care to ensure smooth journeys and continuous patient care through to adulthood.
Identification and support of adults living with SMA who are not currently under the care of a neuromuscular centre.
Advancing disease education
Educational initiatives within the SMA community (including healthcare professionals, people living with SMA, their families etc) and the general public to raise awareness and understanding of SMA, including the management of expectations in an evolving landscape.
Service considerations
Service considerations such as scheduling, community-based services and others to help the experience of people living with SMA and their support network.
If you have an idea for a project or activity that does not align with the themes included in this call for grants programme please go to our website for more information on our standard grant process website:
In 2025, Roche is planning to offer two application windows for submissions aligned with our prioritised themes. Applications for this grant programme will only be accepted during these designated periods. For the first application window, forms must be submitted by 20th March 2025. The second window will open in summer 2025.
The approval of grant applications is subject to, but not limited to, the following principles:
The activity must be delivered independently without the involvement of Roche, apart from the financial contribution agreed.
There will be a written agreement between the recipient organisation and Roche.
The funding activity is agreed for a defined period of time and must be clearly and unambiguously described and defined.
Roche does not receive any benefits from supporting the activity approved for the grant.
Any associated materials or activities must clearly disclose Roche’s financial support if the grant is provided.
As Roche adheres to the ABPI Code of Practice, we are not able to support certain activities. For more information on activities that can be supported, please visit our website
The start date of the activity must not be earlier than the 1st May 2025, to allow for approval time and payment.
We recommend individual grant proposals range between approximately £1,000 and £15,000. However, if your proposal exceeds this upper limit, we encourage you to submit it nonetheless, as we may still be able to consider it.
Applicants are required to submit their proposals by downloading and completing the application form from this page and send with a supporting letter. Both of these should be emailed to
The application will ask for the following information:
Organisation details, contact information and registration number (if applicable).
Proposal description, including background, scope, SMART goals and anticipated impact.
Budget breakdown, funding request and financial compliance.
Timeline and project management plan with defined milestones.
The supporting letter should be:
In PDF format
On official headed paper
Dated
Include the grant proposal title, aims and goals
Signed by an authorised representative of the organisation (an electronic signature is acceptable).
Further guidance on how to apply for a grant and the types of activities that can be funded can be found on our website
Roche will endeavor to communicate their decision with applicants within 2 weeks of the deadline, unless they directly confirm otherwise. Applications will be reviewed in line with the prioritised themes outlined previously. If applicants have been successful funding will be provided within 3 weeks of the deadline (subject to both parties signing the written agreement). However, if you are unsuccessful in this application window, we will provide you with feedback.
If your grant request is approved, Roche Products Ltd will issue a draft agreement outlining the terms of payment and other relevant conditions. Upon mutual agreement and signing of the final document, Roche will proceed with the grant payment.
Once the funded activity is completed, Roche will require evidence that the activity took place. An example of this evidence could be: a report detailing how the defined milestones were met, or a summary of an educational meeting.
If you have any questions about the programme please send an email to, with the subject line Call for Grants in SMA Programme 2025 Query:
We look forward to receiving your educational grant application.
M-GB-00021030
In order for Roche to assess educational grant applications, it will be necessary to store and process the information that applicants send to Roche. Data will be held securely and lawfully processed, will be kept up-to-date, and not retained for longer than necessary. An applicant will
be deemed to have given their explicit consent to Roche to process the data they have sent us in their application, in accordance with the UK General Data Protection Regulation by signing a letter of application for the educational grant.
Roche is required by the ABPI Code of Practice to disclose any payments made to healthcare organisations, healthcare-related entities or patient organisations. We shall disclose any successful grant payment on our UK corporate website.
About Roche
Roche is a pioneer in pharmaceuticals and diagnostics, focused on advancing science to improve people’s lives. We have created truly differentiated medicines in oncology, immunology, infectious diseases and diseases of the central nervous system. In the UK, we employ over 2,000 people who work hard every day to bring our medicines and diagnostics to people who urgently need them. We work from bench to bedside - researching new medicines and diagnostics, running global clinical trials, and collaborating with the NHS to try to ensure rapid uptake and delivery of our products and services. For more information please visit:
M-GB-00021030 Date of Preparation: January 2025
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.